✓ Translated by DotMD AI Clinical Council Source: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36813177 ↗

Phase III Randomized Trial: Accurate tumor segmentation and treatment outcome prediction with DeepTOP

Original Paper Title: “Accurate tumor segmentation and treatment outcome prediction with DeepTOP”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • DeepTOP is open to provide a tractable framework for the development of other segmentation and predicting tools in clinical settings. DeepTOP-based tumor assessment can provide a reference for clinical decision making and facilitate imaging marker-driven trial design.
  • Study Design & Sample: Phase III Randomized Trial published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Accurate outcome prediction prior to treatment can facilitate trial design and clinical decision making to achieve better treatment outcome. Key clinical takeaway: DeepTOP is open to provide a tractable framework for the development of other segmentation and predicting tools in clinical settings. DeepTOP-based tumor assessment can provide a reference for clinical decision making and facilitate imaging marker-driven trial design.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023-06-15; Phase III Randomized Trial; Rigor 82/100): DeepTOP is open to provide a tractable framework for the development of other segmentation and predicting tools in clinical settings. DeepTOP-based tumor assessment can provide a reference for clinical decision making and facilitate imaging marker-driven trial design.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: adenosquamous-carcinoma → Condition: lymphomatoid-papulosis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36813177: Phase III Randomized Trial: Accurate tumor segmentation and treatment outcome prediction with DeepTOP

3 of 3 Free Questions Remaining